GSK shares face dividend cut: should I keep buying?

The GSK share price has disappointed investors for many years. But as Roland Head explains, changes under way should improve performance.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

A GlaxoSmithKline scientist uses a microscope

Image: GlaxoSmithKline

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) shares rose and then fell back on Wednesday, after the company updated investors on its plans to split the business and cut the dividend next year.

Although I’m optimistic about the split, I think that Glaxo shareholders are probably right to be cautious after years of underperformance. The GSK share price has fallen by 14% over the last year and is 5% lower than it was five years ago. In contrast, the share price of rival AstraZeneca has doubled over the last five years.

Time to cut my losses?

In 2022, GlaxoSmithKline will be split into two businesses. New GSK will contain the group’s core pharmaceutical and vaccines business. The company’s consumer healthcare division, which owns brands such as Nicorette and Sensodyne, will be separated into a new company.

Existing GSK shareholders — like me — will receive shares in the new consumer business, which will be listed on the London Stock Exchange. But we’ll have to stomach a big dividend cut. CEO Dame Emma Walmsley says that the total dividend paid by the two businesses next year is expected to be 55p. That’s 30% below the current payout of 80p.

As an income investor, I’ll often sell a stock that cuts its dividend. But in this case, I think what’s happening is that Glaxo’s current management is trying to fix problems that existed before taking charge.

Although I’ve been happy to receive a fat 6% yield from my GSK shares in recent years, I’ve always thought that the payout looked stretched. I’m not going to sell my shares simply because of the dividend cut.

Split could boost growth

Splitting GlaxoSmithKline will create two smaller, more focused businesses. Over time, I think this should lead to better performance and a higher valuation.

However, I think that these plans are also being shaped by Glaxo’s problems — growth has been sluggish and debt is quite high. It looks like the consumer healthcare business will take on a sizeable amount of the group’s existing debt. This should ease the pressure on the pharma business, so it can increase spending on research and development.

I think this is a fair plan, but there are no free lunches. The consumer business is expected to start trading with net debt of four times EBITDA (a measure of earnings). That’s much higher than the 2.4x EBITDA multiple reported by rival Reckitt at the end of 2020. I expect dividends from the new business to be limited until management has paid down some of this debt.

I’d still buy GSK shares

Despite my critical comments, I still see GlaxoSmithKline as an attractive business to own in a long-term portfolio.

I expect the company’s core consumer and pharmaceuticals markets to benefit from long-term global growth.

Management guidance is for the core pharma business to deliver 10% annual profit growth over the next five years. If the company can deliver on this, I think Glaxo shares are probably cheap at current levels.

Am I going to sell my GSK shares? No, I’m not. Although the company faces some challenges, I think that the changes under way should help to fix them. As things stand today, I’d rather be a buyer today than a seller.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »